Startup profile · funding coverage
AKASA funding, valuation and investors
Generative AI platform automating healthcare revenue cycle operations.
Keep track of AKASA
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$120M · June 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$180M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · South San Francisco, California
Investors in latest funding
Other: Andreessen Horowitz , Coatue
Overview
AKASA uses generative AI to automate healthcare revenue cycle tasks — medical coding, prior authorization, claims, and denials — for hospitals and health systems.
Why AKASA is interesting
Unified automation for medical coding, prior auth, and claims — deployed across 650+ hospitals in customer base per company site.
Product & use cases
AKASA uses generative AI to automate healthcare revenue cycle tasks — medical coding, prior authorization, claims, and denials — for hospitals and health systems.
- Medical coding and claims automation for hospital revenue cycle teams
- Prior authorization workflow automation
- Denial prevention and revenue recovery for health systems
Key facts
- Series C (Jun 2024): $120M; a16z among investors (CB Insights / VCBacked)
- Series B (Mar 2021): $60M led by BOND with a16z and Costanoa (AKASA press)
- Series A (2019): led by a16z Bio + Health
- Deployed across 650+ hospitals and 6,500 outpatient facilities per company reporting
Funding history (newest first)
Series B
2021 $60MSource: Series B (2021): $60M led by BOND with a16z and Costanoa participation (company press)
Series A
2019Source: Series A (2019): led by a16z Bio + Health (a16z announcement)
Investors in our directory
Funds linked from AKASA's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Hospital revenue cycle remains labor-intensive for coding, prior auth, and denials. AKASA's GenAI platform with expert-in-the-loop targets health systems representing $120B+ in net patient revenue. Competes with AI-native RCM startups and legacy vendors like Waystar; moat depends on EHR integration depth and coding accuracy on clinician gold sets.
-
Thoughtful AI direct
AI RCM automation competitor.
-
Olive AI adjacent
Prior RCM automation entrant (wind-down); AKASA focuses on unified GenAI platform.
-
Epic revenue cycle modules incumbent
EHR-native RCM; AKASA integrates within existing EHR workflows.
-
Waystar incumbent
Legacy RCM software; less AI-native than AKASA's GenAI approach.
Notable stories
- Series A (2019): led by a16z Bio + Health (a16z announcement)
- Series B (2021): $60M led by BOND with a16z and Costanoa participation (company press)
Industries
Related funding articles
Venture Capital Tracker pieces that cover AKASA's financing or category context.
FAQs about AKASA
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.